Structure, Employment and Performance in Biotech Firms

OPEN ARCHIVE

Union Jack
Dannebrog

Structure, Employment and Performance in Biotech Firms

Show simple item record

dc.contributor.author Lund Jensen, Rasmus en_US
dc.contributor.author Dahlgren, Henrich en_US
dc.contributor.author Valentin, Finn en_US
dc.date.accessioned 2009-02-04T10:24:47Z
dc.date.available 2009-02-04T10:24:47Z
dc.date.issued 2007-01-02T00:00:00Z en_US
dc.identifier.isbn 8791549140 en_US
dc.identifier.uri http://hdl.handle.net/10398/6781
dc.description.abstract This report studies employment effects associated with the adoption of modern biotechnology in Danish industry. In this context we also examine industry structure, patterns of job creation, key outputs such as patents and the pipeline of projects in clinical trials. To see the development of Danish biotech firms in a relevant context we compare a Danish segment of biotech firms with a matching Swedish segment. From an overall assessment modern biotechnology, despite the three decades elapsed since the first genetic manipulation, is still in a stage of experimentation, learning how to turn its new tools and approaches into an operational, reliable, cost-effective technology, sufficiently "pluggable” with other technologies. Therefore employment directly related to biotech is particularly visible and identifiable in firms focused on R&D. Outside this core of R&D activity other industries appear as early adopters of biotech, but only parts of their activities relate to modern biotechnology. From the outside it is difficult to isolate what share of their employment is attributable to their activities within biotechnology. In pursuit of clarity on the role of biotechnology this report studies a segment of Drug Discovery Firms (DDFs), which almost exclusively are based on capabilities in biotech research. This delimitation gives the advantage of studying a homogenous segment of firms. At the same time, this segment of biotech research firms is an informative indicator of the ability of the Danish economy to perform in the transition towards knowledge and sciencebased competitiveness. That is so because DDFs to an unusual extent depend on the ability of their framework to perform as an innovation system, by which we refer to advantages growing out of interactions and complementarities between e.g. universities, firms and venture capital. That makes DDFs a sensitive "seismograph" for the ability of the Danish innovation system to foster new science-based technologies. Key words: Employment, Biotechnology, Firm size distribution, Industry structure, Firm performance JEL Codes: J21, L11, L22, L25, L65, O57 en_US
dc.format.extent 23 s. en_US
dc.language eng en_US
dc.relation.ispartofseries Biotech Business Working paper;2006-005 en_US
dc.subject.other performance en_US
dc.subject.other industristruktur en_US
dc.subject.other firm size distribution en_US
dc.subject.other ansættelse en_US
dc.subject.other bioteknologi en_US
dc.title Structure, Employment and Performance in Biotech Firms en_US
dc.type wp en_US
dc.accessionstatus modt07jan02 mielmo en_US
dc.contributor.corporation Copenhagen Business School. CBS en_US
dc.contributor.department Research Centre on Biotech Business en_US
dc.contributor.departmentshort BIOTECH en_US
dc.contributor.departmentuk Research Centre on Biotech Business en_US
dc.contributor.departmentukshort BIOTECH en_US
dc.idnumber 8791549140 en_US
dc.publisher.city København en_US
dc.publisher.year 2006 en_US
dc.title.subtitle Comparison of Danish and Swedish drug discovery firms en_US


Creative Commons License This work is licensed under a Creative Commons License.

Files Size Format View
wp05-2006.pdf 384.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record